Modus announces outcome of the first exercise period for warrants of series TO 2030; receives approximately SEK 134 thousand
Modus Therapeutics Holding AB (publ) (“Modus” or the “Company”) today announces the outcome of the first exercise period for warrants of series TO 2030, which were issued in connection with the rights issue carried out in the summer of 2025. In total, 335,166 warrants of series TO 2030 were exercised and the Company will thereby receive approximately SEK 134 thousand before issue costs.
Of the total 38,084,264 warrants of series TO 2030 issued, 335,166 warrants were exercised for subscription of 335,166 new shares in the Company at a subscription price of SEK 0.40 per share, corresponding to an exercise rate of approximately 0.88 percent. Through the exercise of the warrants, the Company receives approximately SEK 134 thousand before issue costs.
The now completed exercise period constituted the first of a total of five exercise periods for the warrants, which run until 2030. Holders who have not exercised their warrants have the opportunity to do so during the remaining four periods: 13–26 September 2027, 18–30 September 2028, 18–29 September 2029 and 16–28 September 2030.
Number of shares, share capital and dilution
Through the exercise of warrants of series TO 2030, the number of shares in the Company increases by 335,166, from 168,701,791 to 169,036,957, and the share capital increases by SEK 20,109.96, from SEK 10,122,107.46 to SEK 10,142,217.42, corresponding to a dilution of approximately 0.20 percent.
Issuing agent
Bergs Securities AB acts as issuing agent.
This information
This information was submitted for publication, through the agency of the contact persons below, on 29 September 2026 at 14:00 CEST.
For more information on Modus Therapeutics, please contact:
John Öhd, CEO, Modus Therapeutics
Phone: +46 (0) 70 766 80 97
Email: john.ohd@modustx.com
Certified Adviser
Bergs Securities AB
Hemsida: www.bergssecurities.se
About Modus Therapeutics and sevuparin
Modus is a Swedish biotech company developing its patented polysaccharide, sevuparin, as a treatment option for several major unmet medical needs, including anemia in kidney disease and other chronic inflammatory conditions, severe malaria, sepsis, and other disorders involving severe systemic inflammation. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com.
Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.